Connect your AI

Qualys, Inc. QLYS Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF

Heartflow, Inc. Common StockHTFL

$15.41M-25.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.19M-50.8%

Lantheus HoldingsLNTH

$6.19M-79.2%

Tarsus Pharmaceuticals, Inc.TARS

$7.96M-63.4%

Kulicke & Soffa IndustriesKLIC

$7M-11.5%

Oruka Therapeutics, Inc.ORKA

$25.07M+128%

Other financials

Income statement

Revenue$175.6M+9.8%

Gross profit$145.6M+11.2%

Operating income$60.9M+17.6%

Net income$50.6M+6.5%

EPS (diluted)$1.42+10.1%

Balance sheet

Cash & equivalents$247.1M+4.7%

Total debt$52.2M+7.4%

Total equity$569.9M+14.4%

Total assets$1.1B+9.9%

Cash flow

Operating cash flow$95.3M-13.0%

CapEx$1.7M-18.2%

Free cash flow$93.6M-12.9%

Valuation

Market cap$3.96B-31.8%

Profitability

Gross margin83.1%+1.3pp

Operating margin33.7%+2.5pp

Net margin29.4%+0.2pp

FCF margin42.4%+1.3pp

Returns & leverage

Return on equity37.7%-2.5pp

Debt / equity0.1×0.0×

Current ratio1.4×0.0×

Where this comes from

Reported directly by Qualys, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Qualys, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Qualys, Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Qualys, Inc.'s indefinite-lived research and development assets?: Qualys, Inc. (QLYS) reported indefinite-lived research and development assets of $40K in Q1 2026.
How has Qualys, Inc.'s indefinite-lived research and development assets changed year-over-year?: Qualys, Inc.'s indefinite-lived research and development assets decreased by 0.0% year-over-year, from $40K to $40K.